TG THERAPEUTICS INC. - COMMON STOCK

TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones

14 1月 2025 06:00:00 条件 Nasdaq GlobeNewswire

TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

09 1月 2025 06:30:00 条件 Nasdaq GlobeNewswire

TG Therapeutics to Participate in the Evercore HealthCONx Conference

29 11月 2024 07:00:00 条件 Nasdaq GlobeNewswire

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

25 11月 2024 08:47:54 条件 NetDania Notify

TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

21 11月 2024 05:00:00 条件 Nasdaq GlobeNewswire

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

14 11月 2024 08:55:54 条件 NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

13 11月 2024 10:43:19 条件 NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

12 11月 2024 08:50:33 条件 NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

11 11月 2024 08:45:41 条件 NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

08 11月 2024 13:45:51 条件 NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

07 11月 2024 09:01:11 条件 NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

06 11月 2024 08:45:06 条件 NetDania Notify

TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

04 11月 2024 06:00:00 条件 Nasdaq GlobeNewswire

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

01 11月 2024 10:54:23 条件 NetDania Notify

TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

01 11月 2024 07:06:02 条件 Nasdaq GlobeNewswire

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

18 9月 2024 08:45:02 条件 NetDania Notify

New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis

18 9月 2024 06:15:00 条件 Nasdaq GlobeNewswire

New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment

18 9月 2024 06:00:03 条件 Nasdaq GlobeNewswire

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

17 9月 2024 11:04:03 条件 NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

16 9月 2024 13:44:05 条件 NetDania Notify